NEW YORK, Aug 15 - GlaxoSmithKline has agreed to a multi-year, non-exclusive sublicense to Lexicon Genetic’s gene targeting technologies, Lexicon said Wednesday.

The deal brings the total number of licensees for the technologies to 15.

Under the terms of the agreement, GlaxoSmithKline will pay a one-time fee of an undisclosed amount.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

American scientists find themselves once again warning the Trump administration not to dismiss science, the New Yorker report.

A new study suggests CRISPR could be used to save coral reefs from dying off, Forbes reports.

Researchers have found that the i-motif shape of DNA previously observed in the lab also exists in human cells, and that it may serve a purpose.

In PNAS this week: a genomic, transcriptomic, and metabolomic analysis of the tea plant, Arabidopsis thaliana's adaptations to specific local environments, and more.